Cost–Benefit Analysis of Hydrogen Breath Test–Directed Rifaximin for Treatment of Diarrhea-Predominant IBS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Gastroenterology and Hepatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cost-Benefit Analysis of Hydrogen Breath Test-Directed Rifaximin for Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
Clin. Gastroenterol. Hepatol. 2022 Sep 21;[EPub Ahead of Print], A Muratore, ED Shah, WW ChanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.